TKNO · XBRL financial data

Alpha Teknova financial statements, every fiscal year

The same tables from 8 filings, lined up. Matched by XBRL tag: renamed lines keep their history.

How these numbers work

Every number comes from the company's XBRL financial data filed with the SEC, and each one links to its filing.
Lines are matched by XBRL tag, so a line renamed between filings keeps its history.
* marks a quarter worked out from the filing totals: the 10-K year minus the first three quarters, or a year-to-date total minus the earlier one. Fourth-quarter earnings per share is fourth-quarter net income over the fourth-quarter weighted shares.
0 means a filing states zero; a dash (—) means no filing states that number.
“year only” means the 10-K gives the full year but not the quarters needed to work out the fourth. A worked-out quarter of revenue, cost of revenue or operating cash flow more than twice the company's largest quarter of the two years before is shown this way too.
Gross profit is shown as the company reports it; a worked-out quarter must equal revenue less cost of revenue for that quarter, or it is a dash.
Operating income can be above gross profit when the company books other operating income between the two, shown on its own line.
Shares outstanding come from each filing's cover page, as of the date printed there.
Quarters are fiscal: Q2 FY27 is the second quarter of the company's fiscal 2027.

Income statement

Fiscal years (TKNO's year ends in late December)

In thousands of dollars	FY 2021Dec 31, 2021	FY 2022Dec 31, 2022	FY 2023Dec 31, 2023	FY 2024Dec 31, 2024	FY 2025Dec 31, 2025
Revenue from contracts with customers	36,893	41,420	36,684	37,745	40,520
Cost of goods and services sold	19,272	23,944	26,388	30,514	27,079
Gross profit	17,621	17,476	10,296	7,231	13,441
Research and development	4,312	7,737	5,567	2,759	2,197
General and administrative	20,392	28,298	25,450	23,150	20,318
Total operating expenses	29,629	67,135	45,859	33,377	30,417
Operating income (loss)	(12,008)	(49,659)	(35,563)	(26,146)	(16,976)
Other income (expense)	(40)	55	142	0	—
Income tax expense (benefit)	(2,834)	(1,923)	(298)	(88)	58
Net income (loss)	(9,803)	(47,468)	(36,780)	(26,745)	(17,259)
Earnings per share, basic USD per share	(0.61)	(1.69)	(1.16)	(0.57)	(0.32)
Earnings per share, diluted USD per share	(0.61)	(1.69)	(1.16)	(0.57)	(0.32)
Weighted average shares, basic thousands of shares	16,088	28,084	31,820	46,746	53,483
Weighted average shares, diluted thousands of shares	16,088	28,084	31,820	46,746	53,483

Fiscal years (TKNO's year ends in late December)

In thousands of dollars	FY 2021Dec 31, 2021	FY 2022Dec 31, 2022	FY 2023Dec 31, 2023	FY 2024Dec 31, 2024	FY 2025Dec 31, 2025
Cash and cash equivalents	87,518	42,236	28,484	3,708	5,912
Short-term investments	—	—	0	26,688	15,426
Marketable securities	0	—	—	—	—
Accounts receivable	4,666	4,261	3,948	4,312	4,618
Inventory	5,394	12,247	11,594	6,801	7,054
Prepaid and other current assets	2,438	2,374	1,634	1,267	1,501
Total current assets	101,204	61,140	45,660	42,776	34,511
Property and equipment, net	29,810	51,577	50,364	45,753	41,733
Right-of-use asset	0	19,736	16,472	15,767	14,112
Goodwill	16,613	0	—	—	—
Total assets	166,511	152,261	128,587	118,769	103,584
Accounts payable	2,248	2,449	1,493	825	1,378
Accrued liabilities	5,495	6,203	5,579	4,541	4,283
Current portion of long-term debt	—	0	0	4,045	0
Total current liabilities	7,743	10,875	8,875	11,211	7,537
Long-term debt	—	21,976	13,251	—	—
Lease liability, non-current	0	18,111	15,404	14,884	13,270
Total liabilities	23,308	52,376	38,551	36,375	34,809
Accumulated deficit	(7,538)	(55,006)	(91,786)	(118,531)	(135,790)
Total stockholders' equity	143,203	99,885	90,036	82,394	68,775
Total liabilities and equity	166,511	152,261	128,587	118,769	103,584
Common shares outstanding (cover page) thousands of shares	28,042	28,190	40,823	53,437	53,588

Fiscal years (TKNO's year ends in late December)

In thousands of dollars	FY 2021Dec 31, 2021	FY 2022Dec 31, 2022	FY 2023Dec 31, 2023	FY 2024Dec 31, 2024	FY 2025Dec 31, 2025
Net income (loss)	(9,803)	(47,468)	(36,780)	(26,745)	(17,259)
Stock-based compensation	1,551	3,711	4,137	3,666	3,429
Depreciation and amortization	2,883	3,165	5,660	6,578	6,342
Net cash from operating activities	(9,069)	(27,400)	(18,814)	(12,391)	(8,646)
Purchases of property and equipment	19,877	28,149	7,934	1,125	1,148
Net cash from investing activities	(17,521)	(28,149)	(7,737)	(27,275)	10,699
Proceeds from issuing common stock	—	0	22,503	15,104	0
Proceeds from long-term debt	11,889	10,135	0	—	—
Repayments of long-term debt	0	0	10,000	0	—
Net cash from financing activities	110,793	10,267	12,799	14,890	151
Net change in cash	84,203	(45,282)	(13,752)	(24,776)	2,204

SIC 2835 and related industry codes, similar size. Each row is the latest quarter reported.

How peers are chosen

SIC 2835 and related industry codes with public float (or, where float is missing, quarterly revenue) between 0.2x and 5x the company's.
Each row is the latest quarter the company has reported, named in the Quarter column; when that filing is a 10-K, it is the fourth quarter, never the full year.
Runway shows only for companies burning cash with under $10B of public float.
* marks a quarter worked out from the filing totals: for a 10-K, the year less the first three quarters; for a 10-Q, the year-to-date total less the earlier one.
A cell reading “not reported” means the filings give no figure for that quarter alone.

Company	Cash ($K)	Revenue, quarter ($K)	Operating cash flow, quarter ($K)	Shares outstanding	Runway	Quarter
Alpha Teknova	6,004	12,185	(471)*	53.7M	37.0 quarters	Q2 FY26 10-QJun 30, 2026
Merus	367,491	12,150	(84,917)*	75.8M	7.5 quarters	Q3 FY25 10-QSep 30, 2025
Avalo Therapeutics	85,382	not reported	(19,988)*	53.6M	20.0 quarters	Q2 FY26 10-QJun 30, 2026
Cue Biopharma	17,392	7,877	(29,004)*	7.3M	0.6 quarters	Q2 FY26 10-QJun 30, 2026
Fitlife Brands	1,089	not reported	3,635*	9.4M	—	Q2 FY26 10-QJun 30, 2026
Immucell	8,860	7,186	3,019*	9.1M	—	Q2 FY26 10-QJun 30, 2026
iBio	56,395	0*	(6,228)*	64.3M	14.1 quarters	Q4 FY26 10-KJun 30, 2026
Mersana Therapeutics	56,391	11,009	(3,192)*	5.0M	17.7 quarters	Q3 FY25 10-QSep 30, 2025
Sutro Biopharma	54,335	9,839	(38,290)*	16.6M	4.3 quarters	Q2 FY26 10-QJun 30, 2026

Not investment advice. Not affiliated with the U.S. SEC.